439 related articles for article (PubMed ID: 25529572)
1. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.
Pavot V; Berthet M; Rességuier J; Legaz S; Handké N; Gilbert SC; Paul S; Verrier B
Nanomedicine (Lond); 2014 Dec; 9(17):2703-18. PubMed ID: 25529572
[TBL] [Abstract][Full Text] [Related]
2. Surface-assembled poly(I:C) on PEGylated PLGA microspheres as vaccine adjuvant: APC activation and bystander cell stimulation.
Hafner AM; Corthésy B; Textor M; Merkle HP
Int J Pharm; 2016 Nov; 514(1):176-188. PubMed ID: 27863662
[TBL] [Abstract][Full Text] [Related]
3. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
Jiang W; Gupta RK; Deshpande MC; Schwendeman SP
Adv Drug Deliv Rev; 2005 Jan; 57(3):391-410. PubMed ID: 15560948
[TBL] [Abstract][Full Text] [Related]
5. A simple and robust method for pre-wetting poly (lactic-co-glycolic) acid microspheres.
Wright B; Parmar N; Bozec L; Aguayo SD; Day RM
J Biomater Appl; 2015 Aug; 30(2):147-59. PubMed ID: 25791685
[TBL] [Abstract][Full Text] [Related]
6. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
[TBL] [Abstract][Full Text] [Related]
7. Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines.
Coombes AG; Major D; Wood JM; Hockley DJ; Minor PD; Davis SS
Biomaterials; 1998 Jun; 19(11-12):1073-81. PubMed ID: 9692806
[TBL] [Abstract][Full Text] [Related]
8. Polycation-decorated PLA microspheres induce robust immune responses via commonly used parenteral administration routes.
Chen X; Wang L; Liu Q; Jia J; Liu Y; Zhang W; Ma G; Su Z
Int Immunopharmacol; 2014 Dec; 23(2):592-602. PubMed ID: 25466267
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-lactic-co-glycolic acid) microspheres: morphological effect on protein release.
Kim HK; Park TG
J Control Release; 2004 Jul; 98(1):115-25. PubMed ID: 15245894
[TBL] [Abstract][Full Text] [Related]
10. High glycolic poly (DL lactic co glycolic acid) nanoparticles for controlled release of meropenem.
Nandakumar V; Geetha V; Chittaranjan S; Doble M
Biomed Pharmacother; 2013 Jun; 67(5):431-6. PubMed ID: 23583192
[TBL] [Abstract][Full Text] [Related]
11. PLGA/PLA micro- and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.).
Fredriksen BN; Grip J
Vaccine; 2012 Jan; 30(3):656-67. PubMed ID: 22100638
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
Gupta RK; Chang AC; Siber GR
Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens.
Kofler N; Ruedl C; Klima J; Recheis H; Böck G; Wick G; Wolf H
J Immunol Methods; 1996 Jun; 192(1-2):25-35. PubMed ID: 8699019
[TBL] [Abstract][Full Text] [Related]
14. Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip.
Grayson AC; Voskerician G; Lynn A; Anderson JM; Cima MJ; Langer R
J Biomater Sci Polym Ed; 2004; 15(10):1281-304. PubMed ID: 15559850
[TBL] [Abstract][Full Text] [Related]
15. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine.
Thomas C; Rawat A; Hope-Weeks L; Ahsan F
Mol Pharm; 2011 Apr; 8(2):405-15. PubMed ID: 21189035
[TBL] [Abstract][Full Text] [Related]
16. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
Singh D; Somani VK; Aggarwal S; Bhatnagar R
Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
[TBL] [Abstract][Full Text] [Related]
17. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation.
Silva AL; Rosalia RA; Varypataki E; Sibuea S; Ossendorp F; Jiskoot W
Vaccine; 2015 Feb; 33(7):847-54. PubMed ID: 25576216
[TBL] [Abstract][Full Text] [Related]
18. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
19. Controlling degradation of acid-hydrolyzable pluronic hydrogels by physical entrapment of poly(lactic acid-co-glycolic acid) microspheres.
Lee JB; Chun KW; Yoon JJ; Park TG
Macromol Biosci; 2004 Oct; 4(10):957-62. PubMed ID: 15487026
[TBL] [Abstract][Full Text] [Related]
20. Poly(lactic acid)-based particulate systems are promising tools for immune modulation.
Peres C; Matos AI; Conniot J; Sainz V; Zupančič E; Silva JM; Graça L; Sá Gaspar R; Préat V; Florindo HF
Acta Biomater; 2017 Jan; 48():41-57. PubMed ID: 27826003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
